Recon: Baxter in late-stage talks for $10B Hillrom buy; Catalent drops $1B for gummy vitamin maker
ReconKari Oakes
Biologics/ biosimilars/ vaccinesGlobalMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyReconKari OakesBiologics/ biosimilars/ vaccinesGlobalMedical DevicesPharmaceuticalsRegulatory Intelligence/Policy